600812.SH
华北制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 4.61
−6.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.8B | 9.2B | 9.9B | 10.1B | 10.5B |
| Cost of Revenue | 6.1B | 6.4B | 6.7B | 6.9B | 7.0B |
| Gross Profit | 2.7B | 2.9B | 3.2B | 3.2B | 3.5B |
| Operating Expenses | |||||
| R&D Expense | 355.7M | 341.0M | 337.3M | 297.2M | 217.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 552.6M | 554.1M | 581.9M | 630.2M | 586.4M |
| Selling & Marketing Expense | 1.1B | 1.2B | 1.4B | 1.7B | 1.8B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.5B | 2.6B | 2.9B | 3.2B | 3.3B |
| Cost and Expenses | 8.6B | 9.0B | 9.6B | 10.0B | 10.3B |
| Operating Income (EBIT) | 317.6M | 354.0M | 311.7M | 156.5M | (567.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 320.5M | 357.4M | 309.8M | 158.5M | (565.1M) |
| Income Tax Expense | 90.3M | 100.0M | 94.9M | 109.1M | 113.7M |
| Bottom Line | |||||
| Net Income | 161.0M | 183.1M | 127.0M | 4.9M | (689.2M) |
| Earnings from Cont. Ops | 230.2M | 257.5M | 215.0M | 49.4M | (678.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 161.0M | 183.1M | 127.0M | 4.9M | (689.2M) |
| Per Share | |||||
| Basic EPS | CN¥0.09 | CN¥0.11 | CN¥0.07 | CN¥0.00 | (CN¥0.40) |
| Diluted EPS | CN¥0.09 | CN¥0.11 | CN¥0.07 | CN¥0.00 | (CN¥0.40) |
| Revenue Per Share | CN¥5.22 | CN¥5.40 | CN¥5.75 | CN¥6.21 | CN¥6.12 |
| Shares | |||||
| Basic Shares Outstanding | 1.7B | 1.7B | 1.7B | 1.6B | 1.7B |
| Diluted Shares Outstanding | 1.7B | 1.7B | 1.7B | 1.6B | 1.7B |
| Profitability Metrics | |||||
| EBITDA | — | 1.3B | 1.1B | 906.3M | 154.8M |
| D&A | — | 908.9M | 805.0M | 749.8M | 722.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026